Abstract
Background
Methods
Results
Notes
AUTHOR CONTRIBUTIONS
Conceptualization: BKJH, RTF, PG. Methodology: BKJH, AK (Adarsh Katamreddy), JSG, JYY, RTF, PG. Formal analysis: BKJH, ASN, AK (Adarsh Katamreddy), JYY, PG. Data curation: BKJH, ASN, OLO, AK (Ankit Kushwaha), AK (Ankita Krishnan), MN. Project administration: BKJH, LP, JM, ST, SM, AG, HG, MS, RTF, PG. Visualization: BKJH, PG. Writing - Original draft: ASN, AK (Adarsh Katamreddy), JSG, JYY, MS, PG. Writing - Review and editing: BKJH, ASN, AK (Adarsh Katamreddy), OLO, AK (Ankit Kushwaha), AK (Ankita Krishnan), MN, LP, JM, ST, SM, AG, HG, MS, RTF, PG. Writing–review & editing: all authors.
REFERENCES
Table 1.
Variable | Non-SIC (n=340) | SIC (n=19) | P-valuea |
---|---|---|---|
Age (yr) | 67±16 | 64±18 | 0.412 |
Female sex | 185 (54.4) | 12 (63.2) | 0.541 |
Diabetes mellitus | 137 (40.2) | 11 (57.9) | 0.101 |
Hypertension | 224 (65.9) | 12 (63.2) | 0.803 |
CAD | 58 (17.1) | 4 (21.1) | 0.734 |
History of heart failure | 59 (17.4) | 7 (36.8) | 0.029 |
ESRD | 28 (8.2) | 1 (5.3) | 0.591 |
History of CVA | 78 (22.9) | 3 (15.8) | 0.502 |
COPD | 73 (21.5) | 5 (26.3) | 0.613 |
Cirrhosis | 31 (9.1) | 2 (10.5) | 0.804 |
Beta-blocker use | 128 (38.0) | 9 (47.4) | 0.565 |
APACHE II score | 19 (13.0–24.2) | 22 (18.5–27.5) | 0.016 |
Lactate (mmol/L) | 3.2 (1.8–6.4) | 4.6 (3.0–8.3) | 0.108 |
Troponin T (μg/L) | 0.1 (0.0–0.4) | 0.2 (0.0–1.1) | 0.186 |
Albumin (g/dl) | 3.23±0.76 | 2.57±0.63 | <0.001 |
Echocardiographic parameter | |||
LVEF | 64.0 (58.0–70.0) | 30.0 (20.0–37.5) | <0.001 |
Regional wall motion abnormality | 30 (9.0) | 9 (50.0) | <0.001 |
RV dilation | 23 (7.1) | 2 (13.3) | 0.304 |
RV hypokinesis | 25 (7.4) | 13 (68.4) | <0.001 |
Shock requiring vasopressors | 128 (37.6) | 16 (84.2) | <0.001 |
Mechanical ventilation | 151 (44.4) | 17 (89.5) | <0.001 |
Culture positivityb | 140 (41.1) | 17 (89.5) | <0.001 |
Mortality | 60 (17.6) | 8 (42.1) | 0.008 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
SIC: sepsis-induced cardiomyopathy; CAD: coronary artery disease; ESRD: end-stage renal disease; CVA: cerebrovascular accident/transient ischemic accident; COPD: chronic obstructive pulmonary disease; APACHE: Acute Physiology and Chronic Health Evaluation; LVEF: left ventricular ejection fraction; RV: right ventricular.
a P-value for chi-square test (categorial variables: female, diabetes mellitus, hypertension, CAD, history of heart failure, ESRD, CVA, COPD, cirrhosis, regional wall motion abnormality, RV dilation, RV hypokinesis, shock requiring vasopressors, mechanical ventilation, culture positivity, and mortality), ttest (continuous variables: age and albumin), or Kruskal-Wallis test (skewed distribution: lactate, troponin T, and LVEF); significant values P<0.05;
Table 2.
Variable |
Univariable model |
Multivariable model |
||
---|---|---|---|---|
OR (95% CI) | P-valuea | OR (95% CI) | P-valuea | |
Sepsis-induced cardiomyopathy | 4.35 (2.19–8.63) | <0.001 | 4.46 (1.15–18.69) | 0.031 |
Albumin levelb | 0.41 (0.29–0.57) | <0.001 | 0.63 (0.40–0.99) | 0.048 |
APACHE II scorec | 1.77 (1.04–2.27) | <0.001 | 1.11 (0.80–1.58) | 0.503 |
Culture positivityd | 1.81 (1.10–3.01) | 0.022 | 0.84 (0.42–1.64) | 0.612 |
Lactatee | 1.26 (1.18–1.35) | <0.001 | 1.12 (1.13–1.31) | <0.001 |
Shock requiring vasopressors | 7.03 (4.05–12.60) | <0.001 | 1.76 (0.83–3.77) | 0.131 |
Mechanical ventilation | 9.18 (4.98–18.15) | <0.001 | 3.36 (1.52–7.77) | 0.003 |
History of heart failure | 1.29 (0.68–2.36) | 0.407 | ||
Sexf | 1.09 (0.66–1.80) | 0.728 | ||
Ageg | 1.00 (0.99–1.02) | 0.333 | ||
CAD | 1.04 (0.52–1.97) | 0.891 | ||
ESRD | 1.99 (0.85–4.39) | 0.092 | ||
HIV | 0.76 (0.21–2.10) | 0.631 | ||
Troponin Th | 1.00 (0.97–1.02) | 0.844 | ||
Beta-blocker use | 0.66 (0.38–1.11) | 0.132 | ||
History of CVAi | 0.84 (0.35–1.83) | 0.691 | ||
COPD | 1.23 (0.55–2.57) | 0.591 | ||
Cirrhosis | 0.78 (0.18–2.34) | 0.693 | ||
Hypertension | 0.82 (0.49–1.39) | 0.454 | ||
Diabetes mellitus | 1.02 (0.61–1.70) | 0.912 |
OR: odds ratio; CI: confidence interval; APACHE: Acute Physiology and Chronic Health Evaluation; CAD: coronary artery disease; ESRD: end-stage renal disease; HIV: human immunodeficiency virus; CVA: cerebrovascular accident; COPD: chronic obstructive pulmonary disease.
Table 3.
Variable |
Univariable model |
Multivariable model |
||
---|---|---|---|---|
OR (95% CI) | P-valuea | OR (95% CI) | P-valuea | |
Albumin levelb | 0.55 (0.36–0.84) | 0.006 | 0.47 (0.23–0.93) | 0.031 |
History of heart failure | 3.15 (1.53–6.34) | 0.001 | 2.72 (0.87–8.10) | 0.072 |
APACHE II scorec | 1.53 (1.13–2.09) | 0.007 | 1.10 (0.66–1.88) | 0.714 |
Culture positivityd | 3.47 (1.74–7.32) | <0.001 | 8.47 (2.24–55.61) | 0.006 |
Shock requiring vasopressors | 8.91 (2.90–38.87) | <0.001 | 2.23 (0.57–11.39) | 0.271 |
Mechanical ventilation | 10.75 (3.02–68.48) | 0.002 | 4.38 (0.95–32.08) | 0.081 |
Sexe | 1.01 (0.52–1.99) | 0.954 | ||
Agef | 1.01 (0.99–1.03) | 0.212 | ||
CAD | 2.00 (0.90–4.16) | 0.073 | ||
ESRD | 1.75 (0.56–4.56) | 0.284 | ||
HIV | 1.90 (0.53–5.45) | 0.271 | ||
Lactateg | 1.04 (0.98–1.11) | 0.152 | ||
Troponin Th | 0.98 (0.87–1.01) | 0.644 | ||
Beta-blocker use | 1.51 (0.77–2.93) | 0.221 | ||
Diabetes mellitus | 2.03 (0.80–5.39) | 0.143 | ||
Hypertension | 0.89 (0.35–2.46) | 0.821 |
SIC: sepsis-induced cardiomyopathy; OR: odds ratio; CI: confidence interval; APACHE: Acute Physiology And Chronic Health Evaluation; CAD: coronary artery disease; ESRD: end-stage renal disease; HIV: human immunodeficiency virus.